Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 380 results for "prabhudas lilladher"

Post Q4 commentary important; like banks: P Lilladher

R Sreesankar of Prabhudas Lilladher says commentary post Q4 of FY15 will be important. He recommends investors to ‘accumulate’ pharma stocks though these stocks have outperformed the market in the last 12 months. Money Control, 3 days ago

1 images for "prabhudas lilladher"

Business Standard, 2 months ago

Buy LT: Dilip Bhat

Dilip Bhat of Prabhudas Lilladher is of the view that one can buy LT.
 Money Control2 days ago Buy HDFC, says Dilip Bhat  Money Control2 weeks ago Metal stocks momentum play: Dilip Bhat  Money Control1 month ago Power stocks to do well, metal a momentum play: Prabhudas  Moneycontrol.com1 month ago
Business Standard India

Hold Sun Pharma, says Surajit Pal

Surajit Pal, pharma analyst at Prabhudas Lilladher recommends holding Sun Pharma and feels that one may enter the stock on correction.
 Money Control4 days ago Accumulate Sun Pharmaceutical Industries: Surajit Pal  Money Control3 weeks ago Sun Pharma to buy GSK's opiates biz in Australia  Moneycontrol.com3 weeks ago See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal  Moneycontrol.com4 days ago

Buy Cummins India; target of Rs 1029: P Lilladher

Brokerage house Prabhudas Lilladher is bullish on Cummins India and has recommended 'Buy' rating on the stock with a target price of Rs 1029, in its research report dated March 16, 2015.
 Money Control2 days ago Buy Bank of India; target of Rs 285: P Lilladher  Money Control1 month ago Buy Union Bank; target of Rs 255: P Lilladher  Money Control1 month ago Beg, borrow or steal: Top 7 bank stocks to buy in 2015  Moneycontrol.com2 months ago

Prabhudas Lilladher reiterates `Accumulate` on Polaris Fin Tech

Polaris Financial Technology (Polaris) announced demerger of its Product (Intellect) into an independent entity. As consideration for the demerger, every shareholder of Polaris (Q , N , C , F) * will receive one share of Intellect. The company will ...
 MyIris1 month ago Buy Polaris Consulting; target of Rs 240: P Lilladher  Money Control2 days ago Accumulate Polaris Consulting; target Rs 215: P Lilladher  Money Control2 months ago

Buy KSB Pumps; target of Rs 764: Prabhudas Lilladher

Brokerage house Prabhudas Lilladher is bullish on KSB Pumps and has recommended buy rating on the stock with a target price of Rs 764 in its research report dated March 17, 2015.
 Money Control1 week ago Buy KPIT Technologies; tgt of Rs 270: Prabhudas Lilladher  Money Control1 week ago Buy MM; target of Rs 1310: Prabhudas Lilladher  Money Control1 week ago Buy Mindtree; target of Rs 1530: P Lilladher  Money Control2 weeks ago
Business Standard

India will continue to attract inflows; invest in rate sensitives: Ajay Bodke, Prabhudas Lilladher

Although a rate hike in June cannot be completely ruled out, the chances of it happening in June, based on current data, look remote, Bodke said. India is likely to continue to attract a torrent of FII inflows as well as large FDI inflows in sectors such as ...
 Economic Times1 week ago We see India attracting a torrent of foreign inflows in 2015: Ajay Bodke  Business Standard2 months ago

Large mid-cap stocks to keep an eye on: P Lilladher

Prabhudas Lilladher has come out with its top picks report and suggested few stocks from large cap and midcap space. The research firm is revising their Nifty trading range for the market to 8200-9300 levels for the next three months while maintaining the 12 ...
 Money Control1 week ago Look at ICICI Bank, HDFC, SBI: Ajay Bodke  Money Control2 weeks ago See Nifty in 8200-9300 range: Prabhudas Lilladher  Money Control2 weeks ago Look at HUL: R Sreesankar  INooz2 weeks ago
Business Standard India

Ajay Bodke positive on Aurobindo Pharma, target Rs 1300

Ajay Bodke of Prabhudas Lilladher has a positive stance on Aurobindo Pharma with a target of Rs 1300 in the medium term.
 Money Control2 weeks ago Mkt eager for passage of key bills; buy Britannia: Bodke  Money Control2 weeks ago Aurobindo Pharma extends fall post Q3 results  Business Standard India1 month ago Buy Aurobindo Pharma; target of Rs 1308: P Lilladher  Moneycontrol.com1 month ago

Add Britannia in portfolio, says Ajay Bodke

Ajay Bodke of Prabhudas Lilladher recommends adding Britannia Industries in the core portfolio.
 Money Control2 weeks ago Stay away from metal space: Ajay Bodke  Money Control1 month ago Bharat Forge, Ashok Leyland top picks: Ajay Bodke  Money Control1 month ago Book some profits in paint stocks: Ajay Bodke  Money Control1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - prabhudas lilladher
Get updated on latest news & your favorite topics right in your inbox!
More     Less